Clinical Trial Update: Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of upadacitinib in combination with topical corticosteroids for children aged 2 to under 12 with moderate-to-severe …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING